Diligence memo · auto-generated · as of July 3, 2026
Mnemosyne Pharmaceuticals Inc
Mnemosyne Pharmaceuticals Inc looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Mnemosyne Pharmaceuticals Inc operates in Biotechnology, based in PROVIDENCE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Mnemosyne Pharmaceuticals Inc has raised $24M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $12M on 2012-02-01.
Most recent recorded round closed around 2012-02-01.
Valuation (modeled)modeled
Provath models Mnemosyne Pharmaceuticals Inc at approximately $446M (range $13M–$2.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.23× the median modeled value of Series A Biotechnology companies in 2010–2012 (92 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 14.4 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 71% of Biotechnology peers (4293 compared).
Modeled value ranks above 82% of those peers.
Closest niche peers: Tobira Therapeutics, Inc., Neoprobe Corp, Akebia Therapeutics, Inc., Adimab, LLC, Elevation Pharmaceuticals Inc.
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.